What mattersShow
- The Vancouver-based company is utilizing a partnership with Variational AI to overcome the time constraints inherent in testing…
- Primary sector: AI Infrastructure
- Open the company page to keep the follow-up signal in view.
3C Therapeutics has partnered with Variational AI to integrate generative artificial intelligence into its cancer drug discovery pipeline. The initiative aims to significantly shorten the path from initial concept to laboratory-validated lead candidates for next-generation treatments.
The company develops advanced therapeutics using a proprietary TriCore Degrader-Antibody Conjugate (DAC) system, which delivers protein-degrading payloads selectively to targeted cancer cells. According to CEO Dan Wattier, the primary bottleneck in developing these complex treatments is the sheer time and resources required to physically create and test new compounds in the lab.
The integration of generative AI into DAC development shifts the early research focus from slow physical screening to rapid computational design, accelerating the identification of promising molecular leads.
To overcome this limitation, 3C Therapeutics is adopting Variational AI’s Enki platform. Generative AI allows the team to computationally generate and rank thousands of novel ligand candidates across a much wider chemical space than traditional methods permit. This ability enables them to focus limited laboratory time on the most promising designs from the outset.
The immediate goal for this collaboration is taking these AI-generated ligands, integrating them into the TriCore platform, and selecting a highly viable lead DAC candidate for further development. The company stated it is eager to prove that AI can maintain the necessary potency and selectivity when these designed molecules are synthesized and built into the proprietary system.
This partnership was facilitated through the Integrated Marketplace program, which provided critical support by mitigating the financial risks associated with adopting cutting-edge technology in drug discovery. For 3C Therapeutics, this collaboration reinforces British Columbia’s position as a hub for precision oncology, linking local solution providers and therapeutics companies to advance treatments for patients with limited options.
Get the week’s essential Canadian tech.
Five minutes. One useful email. No noise.
Sources & technical notesShowHide
Where this story is grounded
Use the public signals, research inputs, and editorial framing here to understand how the story was built.
What to evaluate next
This box highlights the systems, workflows, and decisions the article helps you assess.
Stay in the signal after this story.
Follow the company page, then jump into the broader sector hub before you leave the story.
Keep the company context attached as you read the rest of the coverage.
Weekly Canadian tech signals, distilled for operators.
Subscribe to the signalFree weekly briefing • Unsubscribe anytime
A practical checklist for Canadian policy, privacy, procurement, and governance teams who need a quick way to sanity-check AI deployments before they scale.
Request accessFor partnersInterested in supporting independent Canadian tech coverage?
Explore sponsorshipClose
Interested in supporting independent Canadian tech coverage?
Tell us what you want to sponsor.
If you are exploring sponsorship on this article lane, share the audience you want to reach and the scale of the problem you solve. We will route qualified conversations to the commercial team.
Reader-facing, high-signal, and reviewed before any follow-up.
We will route qualified conversations to the commercial team.
Sidebar Deep Dive
This story lane is a strong fit for a contextual placement that stays adjacent to high-context editorial.
A contextual placement alongside high-context editorial for sponsors that benefit from repeated explanatory exposure.